New drug PIT565 takes on tough blood cancers in early trial
NCT ID NCT05397496
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new biologic drug called PIT565 in 61 adults with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see how well it is tolerated. It is an open-label study, meaning everyone knows they are getting the experimental drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PIT565 (a biologic drug given by IV or injection)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat B-cell blood cancers.
What could go wrong
This is a very early Phase 1 trial with only 61 people, focused on safety and dosing. It may not show strong anti-cancer effects, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA (B-NHL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Créteil, 94010, France
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Reggio Emilia, RE, 42123, Italy
-
Novartis Investigative Site
Kashiwa, Chiba, 277-8577, Japan
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
The University of Kansas Clinical Research Ctr
Fairway, Kansas, 66205, United States
-
University Of Miami
Miami, Florida, 33136, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States